Pfizer (PFE) Signs New Drug Discovery Pact Focused On Sec61 Inhibitors

Pfizer (NYSE:PFE) signed a new research collaboration and license agreement with Enodia Therapeutics to develop Sec61 inhibitors. The arrangement centers on small-molecule Sec61 blockers that Enodia is advancing using its proprietary discovery platform. Under the alliance, Pfizer gains rights to discover, develop and potentially commercialize drug candidates that emerge from Enodia's Sec61 programs. This Sec61-focused collaboration with Enodia is an important piece to weigh against the rest...